non-vasospastic subjects
Showing 26 - 50 of >10,000
Normoglycemia, T2DM (Type 2 Diabetes) Trial in New Delhi (Bread, Mango)
Completed
- Normoglycemia
- T2DM (Type 2 Diabetes Mellitus)
- Bread
- Mango
-
New Delhi, Delhi, IndiaFortis CDOC Hospital
Sep 20, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Non-Clear Cell Renal Cell Carcinoma Trial in Duarte (XL092, Nivolumab, Sunitinib Malate)
Recruiting
- Non-Clear Cell Renal Cell Carcinoma
- XL092
- +2 more
-
Duarte, CaliforniaExelixis Clinical Site #1
Jan 13, 2023
Non-invasive Ventilation, Healthy Subjects Trial in Guangdong (Non-invasive high-frequency oscillatory ventilation, Noninvasive
Not yet recruiting
- Non-invasive Ventilation
- Healthy Subjects
- Non-invasive high-frequency oscillatory ventilation
- Noninvasive Bilevel Positive Pressure Ventilation
-
Guangdong, ChinaThe First Affiliated Hospital of Guangzhou Medical University.
Jul 3, 2022
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)
Not yet recruiting
- Advanced Solid Tumor
- Refractory Non-Hodgkin Lymphoma
- (no location specified)
May 28, 2023
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early
Not yet recruiting
- Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
- SHR7280；Ganirelix Acetate Injection simulant
- SHR7280 simulant； Ganirelix Acetate Injection
- (no location specified)
Aug 15, 2023
Real World Evidence Study in Subjects With Wilson's Disease
Not yet recruiting
- Wilson Disease
- NCC-Sp Assay
- (no location specified)
Mar 23, 2023
Hepatic Impairment Trial (Elacestrant diHCl)
Not yet recruiting
- Hepatic Impairment
- Elacestrant dihydrochloride
- (no location specified)
Nov 6, 2023
Lung Cancer, Nonsmall Cell Trial in Sacramento ([18F]F-AraG Imaging)
Enrolling by invitation
- Lung Cancer, Nonsmall Cell
- [18F]F-AraG Imaging
-
Sacramento, CaliforniaUC Davis EXPLORER Molecular Imaging Center
Jan 4, 2023
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection Trial in Farmington, Tyler (AP-PA02, Placebo)
Recruiting
- Non-cystic Fibrosis Bronchiectasis
- +2 more
- AP-PA02
- Placebo
-
Farmington, Connecticut
- +1 more
Jan 13, 2023
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis Trial in Orlando, San Antonio, Kistarcsa (TVB-2640 - 50 mg)
Not yet recruiting
- Non-alcoholic Steatohepatitis
- +2 more
- TVB-2640 - 50 mg
-
Orlando, Florida
- +2 more
Apr 17, 2023
Hypothyroidism Trial (levothyroxine sodium)
Not yet recruiting
- Hypothyroidism
- levothyroxine sodium
- (no location specified)
Apr 9, 2023
Non-valvular Atrial Fibrillation Trial in Tucson, Thousand Oaks (Left Atrial Appendage Closure)
Active, not recruiting
- Non-valvular Atrial Fibrillation
- Left Atrial Appendage Closure
-
Tucson, Arizona
- +1 more
Jan 18, 2023
Solid Tumor Trial in Taichung (HLA-G-CAR.BiTE allogeneic ?d T cells)
Not yet recruiting
- Solid Tumor
- HLA-G-CAR.BiTE allogeneic γδ T cells
-
Taichung, Non-US, TaiwanChina Medical University Hospital
Nov 27, 2023
Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or
Not yet recruiting
- Non-squamous Non-small-cell Lung Cancer
- Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 5, 2023
Non-Alcoholic Steatohepatitis (NASH) Trial in Fort Myers, Sarasota (Pemvidutide, Placebo)
Recruiting
- Non-Alcoholic Steatohepatitis (NASH)
- Pemvidutide
- Placebo
-
Fort Myers, Florida
- +1 more
Aug 10, 2023
Bladder Cancer Trial in Nara, Okayama (FE 999326)
Recruiting
- Bladder Cancer
- FE 999326
-
Nara, Japan
- +1 more
Jan 19, 2023
Subjects With Renal Impairment, Healthy Subjects Trial in Shanghai (Deuremidevir Hydrobromide Tablets)
Recruiting
- Subjects With Renal Impairment
- Healthy Subjects
- Deuremidevir Hydrobromide Tablets
-
Shanghai, Shanghai, ChinaShanghai Xuhui Central Hospital
May 29, 2023
Hepatic Impairment Trial in Chendu (Yimitasvir Phosphate)
Completed
- Hepatic Impairment
- Yimitasvir Phosphate
-
Chendu, Sichuan, ChinaWest China Hospital of Sichuan University
Oct 25, 2022
Glabellar Lines Trial (Botulinum Toxin Type A Injection [HG102], Botulinum Toxin Type A Injection [Botox])
Not yet recruiting
- Glabellar Lines
- Botulinum Toxin Type A Injection [HG102]
- Botulinum Toxin Type A Injection [Botox]
- (no location specified)
Apr 5, 2023
NAFLD Trial (Placebo, 2 cap.LivPhcD/per day, 4 cap.LivPhcD/per day)
Not yet recruiting
- NAFLD
- Placebo
- +3 more
- (no location specified)
Jun 25, 2023
Subacute Delirium Trial in Little Rock (260279 active study product, 260279 )
Recruiting
- Subacute Delirium
- 260279 active study product
- 260279 placebo
-
Little Rock, ArkansasUAMS Center on Aging
Dec 19, 2022
Itching Trial in Vilnius (Remo-Wax® Oil)
Not yet recruiting
- Itching
- Remo-Wax® Oil
-
Vilnius, LithuaniaVilnius University Hospital
Mar 30, 2023
Advanced NSCLC Trial in China (KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein
Enrolling by invitation
- Advanced Non-small Cell Lung Cancer
- KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
- Axitinib
-
Hefei, Anhui, China
- +5 more
Oct 26, 2022